COMMUNIQUÉS West-GlobeNewswire

MannKind to Present at the JMP Securities Life Sciences Conference
12/06/2019
WESTLAKE VILLAGE, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such [...]
Kyo-Dophilus Probiotics For Every Life Stage
12/06/2019
MISSION VIEJO, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Researchers are continuing to discover that blood pressure, cognitive function and even a person’s mood may be highly influenced by the health of the gut [...]
Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
12/06/2019
Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act CORAL GABLES, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit [...]
Better Choice Company Signs Sales and Marketing Letter of Intent with Leading Pet Insurance Provider, PetPremium Inc.
12/06/2019
NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (OTCQB: BTTR) (the “Company” or “Better Choice”), an animal health and wellness CBD company, today announced it has finalized a joint marketing [...]
Cipher Pharmaceuticals Reports Voting Results for the Election of Directors
12/06/2019
MISSISSAUGA, Ontario, June 12, 2019 (GLOBE NEWSWIRE) -- Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for [...]
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
12/06/2019
WALTHAM, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system [...]
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
12/06/2019
Last Treatment Visits Completed; Follow-up Safety Visits Progressing CALGARY, Alberta, June 12, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all [...]
Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board
12/06/2019
AGOURA HILLS, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB: MATN) dedicated to development of innovative treatments for cancer [...]
Altimmune Appoints Will Brown as Chief Financial Officer
12/06/2019
GAITHERSBURG, Md., June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been [...]
NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
12/06/2019
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service [...]
Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
12/06/2019
Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc [...]
NTS Ventures et IHMA annoncent un programme significatif et important axé sur la surveillance de la résistance aux antifongiques : STAR (Tendances de susceptibilité de la résistance aux antifongiques)
12/06/2019
SCHAUMBURG, Illinois, 12 juin 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), un laboratoire de recherche clinique sur la mycologie et les antifongiques, et International Health Management Associates, Inc./IHMA Europe Sàrl [...]
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
12/06/2019
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D [...]
INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions
12/06/2019
Operations to Continue in the Ordinary Course During Court-Supervised Process PHOENIX, June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical [...]
BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery
12/06/2019
SAN CARLOS, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the China [...]
Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference
12/06/2019
CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating [...]
Neos Therapeutics to Present at Two Upcoming June Conferences
12/06/2019
DALLAS and FORT WORTH, Texas, June 12, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) [...]
Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Officer of Helomics
12/06/2019
MINNEAPOLIS, June 12, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug [...]
Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019
12/06/2019
WATERTOWN, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune [...]

Pages